BEAT · Insider Trading
Heartbeam, Inc. Common Stock
Every open-market purchase and sale reported by BEAT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Richard Ferrari | Director | A | +340,625 deriv. | — |
| 2026-10-09 | Kenneth Warwick Nelson III | Director | A | +125,000 deriv. | — |
| 2026-10-09 | Marga Ortigas-Wedekind | Director | A | +175,000 deriv. | — |
| 2026-10-09 | Michael R Jaff | Director | A | +131,250 deriv. | — |
| 2026-10-09 | Willem Elfrink | Director | A | +187,500 deriv. | — |
| 2026-10-09 | George de Urioste | Director | A | +187,500 deriv. | — |
| 2026-07-24 | Branislav Vajdic | President | A | +3,060,870 | — |
| 2026-07-24 | Kenneth Harry Persen | Chief Technology Officer | A | +105,740 | — |
| 2026-07-24 | Tim Cruickshank | CFO | A | +167,760 | — |
| 2013-07-30 | Rebecca W Rimel | Director | A | +13,746 | — |
| 2013-07-30 | Kirk E Gorman | Director | A | +23,627 | — |
| 2013-07-30 | Anthony James Conti | Director | A | +13,746 | — |
| 2013-07-30 | Ronald A Ahrens | Director | A | +24,917 | — |
| 2013-07-30 | Robert J. Rubin | Director | A | +19,547 | — |
| 2013-07-30 | Eric N Prystowsky | Director | A | +13,746 | — |
| 2013-02-21 | Daniel Wisniewski | SVP - Business Operations | A | +19,200 | — |
| 2013-02-21 | Fred Broadway | Senior Vice President | A | +14,820 | — |
| 2013-02-21 | Ronald A Ahrens | Director | Buy | +5,000 | — |
| 2013-02-21 | Heather C Getz | Chief Financial Officer | A | +28,980 | — |
| 2013-02-21 | George Hrenko | Senior Vice President | A | +15,780 | — |
| 2013-02-21 | Anna McNamara | Senior Vice Pres/Clinical Op. | A | +19,282 | — |
| 2013-02-21 | Joseph H Capper | President and CEO | A | +128,400 | — |
| 2013-02-21 | Michael Geldart | Senior Vice President | A | +19,200 | — |
| 2013-02-21 | Peter Ferola | Senior Vice President | A | +16,800 | — |
| 2012-11-20 | Ronald A Ahrens | Director | Buy | +15,000 | +$33.30K |
| 2012-11-13 | Ronald A Ahrens | Director | Buy | +15,000 | +$33.30K |
| 2012-09-06 | Joseph H Capper | President and CEO | Buy | +23,540 | +$53.00K |
| 2012-09-04 | Joseph H Capper | President and CEO | Buy | +2,600 | +$5.93K |
| 2012-08-31 | Joseph H Capper | President and CEO | Buy | +10,800 | +$24.89K |
| 2012-08-29 | Joseph H Capper | President and CEO | Buy | +1,300 | +$2.85K |
| 2012-08-28 | Joseph H Capper | President and CEO | Buy | +1,600 | +$3.39K |
| 2012-08-27 | Joseph H Capper | President and CEO | Buy | +800 | +$1.70K |
| 2012-08-24 | Joseph H Capper | President and CEO | Buy | +9,600 | +$20.00K |
| 2012-08-22 | Joseph H Capper | President and CEO | Buy | +800 | +$1.61K |
| 2012-08-21 | Joseph H Capper | President and CEO | Buy | +14,160 | +$27.90K |
| 2012-08-20 | Joseph H Capper | President and CEO | Buy | +9,800 | +$20.58K |
| 2012-06-13 | Michael Geldart | SVP-Corp Strategy & Bus Dev. | A | +20,000 | — |
| 2012-05-09 | Eric N Prystowsky | Director | A | +27,398 | — |
| 2012-05-09 | Anthony James Conti | Director | A | +54,796 | — |
| 2012-05-09 | Kirk E Gorman | Director | A | +45,807 | — |
| 2012-05-09 | Ronald A Ahrens | Director | A | +49,660 | — |
| 2012-05-09 | Rebecca W Rimel | Director | A | +27,398 | — |
| 2012-05-09 | Robert J. Rubin | Director | A | +38,958 | — |
| 2012-02-23 | George Hrenko | Senior Vice President | A | +23,482 | — |
| 2012-02-23 | Peter Ferola | Senior Vice President | A | +25,000 | — |
| 2012-02-23 | Jareer Kasrawi | Senior Vice President | A | +21,429 | — |
| 2012-02-23 | Anthony Schuler | Senior Vice President | A | +20,645 | — |
| 2012-02-23 | Anna McNamara | Senior Vice Pres/Clinical Op. | A | +28,693 | — |
| 2012-02-23 | Joseph H Capper | President and CEO | A | +191,071 | — |
| 2012-02-23 | Heather C Getz | Chief Financial Officer | A | +39,924 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Branislav Vajdic | President | 3,709,914 | $1.52M |
| Kenneth Harry Persen | Chief Technology Officer | 448,290 | $183.44K |
| Tim Cruickshank | CFO | 239,990 | $98.20K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BEAT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.